Zoetis Slashes 2026 Guidance as Companion Animal Demand Weakens; Q2 Revenue Flat
ZTS is trading near its 52-week low of $71.47 (7.7% above the low).
Summary
Zoetis reported flat Q2 revenue and cut its full-year 2026 adjusted EPS guidance by roughly 10% at the midpoint, citing weaker U.S. companion animal demand and competitive pressure. Restructuring charges are rising as the company launches a cost-cutting program.
Updates
· Benzinga — CFO/COO transition announced: James Saccaro takes over from Wetteny Joseph. Stock rose 3.8% on the day.
Key Events · Earnings and Guidance · ZTS
-
Q2 Revenue Flat, U.S. Companion Animal Down 11%
Total revenue of $2.5 billion was flat year-over-year, but U.S. companion animal sales fell 11% due to softer clinic visits, pet owner price sensitivity, and heightened competition in dermatology and Simparica Trio.
-
Full-Year Guidance Slashed
2026 adjusted diluted EPS guidance cut to $6.15–$6.25 from $6.85–$7.00, with revenue now expected at $9.12–$9.32 billion (organic operational decline of 3% to 1%) versus prior growth of 2% to 5%.
-
Restructuring Charges Surge
Restructuring charges and certain acquisition/divestiture-related costs totaled $77 million in Q2 and $99 million year-to-date, primarily driven by employee termination costs under a new comprehensive cost and productivity program.
-
International and Livestock Provide Offset
International segment revenue grew 8% reported (6% organic operational), and livestock sales rose 12% overall, supported by cattle and poultry strength, partially mitigating the U.S. companion animal weakness.
Analysis · ZTS · Life Sciences
Zoetis reported Q2 revenue flat at $2.5 billion and slashed its full-year 2026 adjusted EPS guidance to $6.15–$6.25, down from $6.85–$7.00 just three months ago. The cut reflects a sharp deterioration in the U.S. companion animal business, where sales fell 11% on price sensitivity and heightened competition in key dermatology and parasiticide franchises. The company is also absorbing $77 million in restructuring charges this quarter as it launches a comprehensive cost and productivity program. While international and livestock segments showed resilience, the guidance reset signals management expects the companion animal headwinds to persist through year-end. The stock is trading near its 52-week low, and this report confirms the operating environment has worsened faster than anticipated.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZTS was trading at $77.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.2B. The 52-week trading range was $71.47 to $160.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.